TTRXHealthcare · BiotechnologyThe 2 Wall Street analysts covering Turn Therapeutics, Inc. hold a median 12-month price target of $25 — +134.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 22 of 100 as at 28 Oct 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Turn Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (84): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Issuance (5): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on TTRX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +134.6% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 23 Oct 2026 | WBB Securities | Upgrade | Hold | $10 |
| 24 Sept 2026 | LUCID CAPITAL MARKETS | Initiates | Buy | $24 |
| 24 Sept 2026 | LUCID CAPITAL MARKETS | Initiates | Buy | — |
| 14 Sept 2026 | WBB Securities | Downgrade | Sell | $10 |
| 14 Sept 2026 | WBB Securities | Downgrade | Sell | — |
| 24 Mar 2026 | D. Boral Capital | Maintains | Buy | $8.00 |
| 24 Mar 2026 | D. Boral Capital | Maintains | Buy | — |
| 20 Jan 2026 | D. Boral Capital | Maintains | Buy | — |
| 29 Dec 2025 | D. Boral Capital | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
TTRX appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 29 Oct 2026, Turn Therapeutics, Inc. returned +103.0% against +13.1% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 99% of US stocks
Cheaper than 1% of US stocks
Cheaper than 93% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 2% of US stocks
Higher than 8% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Turn Therapeutics, Inc. has a market value of $325.5M and an enterprise value of $315.2M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$8.4M.
Free cash flow in the twelve months to 30 June 2026: −$4.5M.
Trailing P/E: −88.8×; forward P/E: −71.5× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Turn Therapeutics, Inc. employs 2 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Turn Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Turn Therapeutics announced that CEO Bradley Burnam and Executive Clinical and Regulatory Lead Stephen M. Hahn will participate in a U.S. Bancorp | BTIG virtual fireside chat on October 28, 2026, at 10:00 a.m. ET.
Why it matters — The event gives TTRX watchers a scheduled opportunity to hear from company leadership about its program.
Turn Therapeutics Inc. (Nasdaq: TTRX) announced that CEO Bradley Burnam and Executive Clinical and Regulatory Lead Stephen M. Hahn, M.D., will present at the Stifel 2026 Virtual Immunology and Inflammation Forum on September 23, 2026 at 1:30 PM ET, with the presentation providing a detailed look at the company's work.
Why it matters — TTRX watchers would be interested because the company's leadership presentation at a Stifel investor forum offers visibility for its targeted therapies for inflammatory skin diseases at a major investment conference.
Turn Therapeutics announced the appointment of Robert R. Redfield, M.D., former CDC Director, as Chief Scientific Officer. Dr. Redfield brings over four decades of experience in immunology, microbiology, infectious disease, clinical research, and public health to the clinical-stage biotech company.
Why it matters — A TTRX watcher would care because adding a former CDC Director with extensive infectious-disease expertise could strengthen the company's scientific leadership as it develops non-systemic therapies for skin diseases.
Turn Therapeutics announced the publication of new peer-reviewed research in the journal Life providing in-vivo evidence that its lead investigational therapy, GX-03, selectively reduces several key inflammatory signals and drivers of itch associated with inflammatory skin disease.
Why it matters — The peer-reviewed in-vivo findings add scientific validation for GX-03, Turn Therapeutics' lead investigational therapy for inflammatory skin conditions.
Turn Therapeutics provided corporate updates and reported financial results for the three and six months ended June 30, 2026. The company's review of interim GX-03 Phase 2 data indicated activity across a broader range of conditions, with management describing the second quarter as one of the most productive in its history.
Why it matters — A Turn Therapeutics watcher would care because the interim GX-03 Phase 2 data update and quarterly financial report provide an early look at the clinical progress and financial position of its lead skin-disease therapy candidate.
The 2 Wall Street analysts covering Turn Therapeutics, Inc. have a median 12-month price target of $25, with estimates ranging from $24 to $26. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 2 analysts covering Turn Therapeutics, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Turn Therapeutics, Inc. 22 out of 100 across roughly 4,600 US stocks as at 28 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 28 Oct 2026, Turn Therapeutics, Inc. ranks 22 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (84 of 100).
No one can know that. What the data says: the median 12-month target from 2 analysts implies +134.6% from the last close, and Ticker Nerd's factor model ranks Turn Therapeutics, Inc. 22 out of 100 as at 28 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Turn Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TTRX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $24 to $26 over the next 12 months.
Turn Therapeutics, Inc. returned +103.0% over the 12 months to 29 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Turn Therapeutics Inc. is a clinical-stage biotechnology and medical device company focused on developing targeted therapies for dermatology, wound care, and infectious disease.
The most recent item we track (Business Wire, 21 Oct 2026): "U.S. Bancorp | BTIG to Host Turn Therapeutics for Virtual Fireside Chat". Turn Therapeutics announced that CEO Bradley Burnam and Executive Clinical and Regulatory Lead Stephen M. Hahn will participate in a U.S. Bancorp | BTIG virtual fireside chat on October 28, 2026, at 10:00 a.m. ET.
Turn Therapeutics Inc. is a clinical-stage biotechnology and medical device company focused on developing targeted therapies for dermatology, wound care, and infectious disease. The company’s product portfolio is built around its proprietary PermaFusion platform, which is designed to improve how active ingredients are delivered and perform in topical treatments. Its current programs include non-systemic therapies for inflammatory skin conditions such as atopic dermatitis, along with treatments for nail and wound-related disorders. Turn Therapeutics also maintains a portfolio of FDA-cleared medical devices and works across healthcare settings that address acute and chronic skin conditions, dermatoses, and infection control. Based in Westlake Village, California, the company operates at the intersection of pharmaceuticals and medical devices, supporting clinicians with localized treatment options designed to act directly at the site of disease.
CEO Mr. Bradley E. Burnam · 2 employees · United States · https://turntherapeutics.com
